JACC
HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
 QUICK SEARCH:   [advanced]


     


J Am Coll Cardiol, 1993; 21:1039-1047
© 1993 by the American College of Cardiology Foundation
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gold, H.
Right arrow Articles by Newell, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gold, H.
Right arrow Articles by Newell, J.

Evidence for a rebound coagulation phenomenon after cessation of a 4-hour infusion of a specific thrombin inhibitor in patients with unstable angina pectoris

HK Gold, FW Torres, HD Garabedian, W Werner, IK Jang, A Khan, JN Hagstrom, T Yasuda, RC Leinbach, JB Newell, et al.

Cardiac Unit, Massachusetts General Hospital, Boston, Massachusetts 02114.

OBJECTIVES. In a Phase I clinical trial, we studied the antithrombotic and clinical effects of the synthetic competitive thrombin inhibitor, argatroban, in 43 patients with unstable angina pectoris. BACKGROUND. Thrombin has a pivotal role in platelet-mediated thrombosis associated with atheromatous plaque rupture in patients with an acute ischemic coronary syndrome. However, the efficacy of conventional heparin therapy to prevent ischemic events is limited and has been surpassed by that of specific thrombin inhibitors in experimental models of arterial thrombosis. METHODS. Intravenous infusion of the drug (0.5 to 5.0 micrograms/kg per min) for 4 h was monitored by sequential measurements of coagulation times and of indexes of thrombin activity in vivo followed by a 24-h clinical observation period. RESULTS. Significant dose-related increases in plasma drug concentrations and activated partial thromboplastin times (aPTT), but no bleeding time prolongation or spontaneous bleeding, was observed. Myocardial ischemia did not occur during therapy but, surprisingly, 9 of the 43 patients experienced an episode of unstable angina 5.8 +/- 2.6 h (mean +/- SD) after infusion. This early recurrent angina was correlated significantly with a higher argatroban dose and with greater prolongation of aPTT but not with other demographic, clinical, laboratory and angiographic characteristics. Pretreatment plasma concentrations of thrombin-antithrombin III complex and fibrinopeptide A were elevated two to three times above normal values. During infusion, thrombin-antithrombin III complex levels remained unchanged, whereas a significant 2.3-fold decrease in fibrinopeptide A concentrations was observed. By contrast, 2 h after infusion, thrombin-antithrombin III complex concentrations increased 3.9-fold over baseline measurements together with return of fibrinopeptide A levels to values before treatment with argatroban. CONCLUSIONS. In patients with unstable angina, argatroban inhibits clotting (aPTT prolongation) and thrombin activity toward fibrinogen (fibrinopeptide A decrease), but in vivo thrombin (thrombin-antithrombin III complex) formation is not suppressed. However, cessation of infusion is associated with rebound thrombin (thrombin-antithrombin III complex) generation and with an early dose-related recurrence of unstable angina. Although the mechanism of this clinical and biochemical rebound phenomenon remains to be determined, its implication for the clinical use of specific thrombin inhibitors in the management of ischemic coronary syndromes may be significant.


This article has been cited by other articles:


Home page
Eur Heart JHome page
A. G.G. Turpie
New oral anticoagulants in atrial fibrillation
Eur. Heart J., January 2, 2008; 29(2): 155 - 165.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
J. Hirsh, M. O'Donnell, and J. I. Weitz
New anticoagulants
Blood, January 15, 2005; 105(2): 453 - 463.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
J. I. Weitz, J. Hirsh, and M. M. Samama
New Anticoagulant Drugs: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
Chest, September 1, 2004; 126(3_suppl): 265S - 286S.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
V. Menon, R. A. Harrington, J. S. Hochman, C. P. Cannon, S. D. Goodman, R. G. Wilcox, H. J. Schunemann, and E. M. Ohman
Thrombolysis and Adjunctive Therapy in Acute Myocardial Infarction: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
Chest, September 1, 2004; 126(3_suppl): 549S - 575S.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
N. R. Bijsterveld, R. J. G. Peters, S. A. Murphy, P. J. L. M. Bernink, J. G. P. Tijssen, M. Cohen, and TIMI 11B/ESSENCE Study Groups
Recurrent cardiac ischemic events early after discontinuation of short-term heparin treatment in acute coronary syndromes: Results from the thrombolysis in myocardial infarction (TIMI) 11B and efficacy and safety of subcutaneous enoxaparin in Non-Q-Wave coronary events (ESSENCE) studies
J. Am. Coll. Cardiol., December 17, 2003; 42(12): 2083 - 2089.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
J. N. Bott, K. Reddy, and S. Krick
Bivalrudin use in off-pump myocardial revascularization in patients with heparin-induced thrombocytopenia
Ann. Thorac. Surg., July 1, 2003; 76(1): 273 - 275.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
J.W. Eikelboom, J.I. Weitz, A. Budaj, F. Zhao, I. Copland, P. Maciejewski, M. Johnston, and S. Yusuf
Clopidogrel does not suppress blood markers of coagulation activation in aspirin-treated patients with non-ST-elevation acute coronary syndromes
Eur. Heart J., November 2, 2002; 23(22): 1771 - 1779.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
N. R. Bijsterveld, A. H. Moons, J. C. M. Meijers, J. G. P. Tijssen, H. R. Buller, M. Levi, and R. J. G. Peters
Rebound thrombin generation after heparin therapy in unstable angina: A randomized comparison between unfractionated and low-molecular-weight heparin
J. Am. Coll. Cardiol., March 6, 2002; 39(5): 811 - 817.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
M. A. Lauer, P. L. Houghtaling, J. G. Peterson, C. B. Granger, D. L. Bhatt, S. K. Sapp, M. L. Simoons, R. A. Harrington, E. J. Topol, and A. M. Lincoff
Attenuation of Rebound Ischemia After Discontinuation of Heparin Therapy by Glycoprotein IIb/IIIa Inhibition With Eptifibatide in Patients With Acute Coronary Syndromes: Observations From the Platelet IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial
Circulation, December 4, 2001; 104(23): 2772 - 2777.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
J. Oldgren, R. Linder, L. Grip, A. Siegbahn, and L. Wallentin
Coagulation Activity and Clinical Outcome in Unstable Coronary Artery Disease
Arterioscler. Thromb. Vasc. Biol., June 1, 2001; 21(6): 1059 - 1064.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
M. C. Bahit, E. J. Topol, R. M. Califf, P. W. Armstrong, D. A. Criger, V. Hasselblad, A. Betriu, J. Hirsh, D. Ardissino, and C. B. Granger
Reactivation of ischemic events in acute coronary syndromes: results from GUSTO-IIb
J. Am. Coll. Cardiol., March 15, 2001; 37(4): 1001 - 1007.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
E. M. Ohman, R. A. Harrington, C. P. Cannon, G. Agnelli, J. A. Cairns, and J.W. Kennedy
Intravenous Thrombolysis in Acute Myocardial Infarction
Chest, January 1, 2001; 119(1_suppl): 253S - 277S.
[Full Text] [PDF]


Home page
ChestHome page
P. Monagle, A. D. Michelson, E. Bovill, and M. Andrew
Antithrombotic Therapy in Children
Chest, January 1, 2001; 119(1_suppl): 344S - 370S.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
R. C. Becker, F. A. Spencer, Y. Li, S. P. Ball, Y. Ma, T. Hurley, and J. Hebert
Thrombin generation after the abrupt cessation of intravenous unfractionated heparin among patients with acute coronary syndromes: Potential mechanisms for heightened prothrombotic potential
J. Am. Coll. Cardiol., October 1, 1999; 34(4): 1020 - 1027.
[Abstract] [Full Text] [PDF]


Home page
CLIN APPL THROMB HEMOSTHome page
J. Fareed, B. E. Lewis, D. D. Callas, D. A. Hoppensteadt, J. M. Walenga, and R. L. Bick
Antithrombin Agents: The New Class of Anticoagulant and Antithrombotic Drugs
Clinical and Applied Thrombosis/Hemostasis, October 1, 1999; 5(1_suppl): S45 - S55.
[Abstract] [PDF]


Home page
Eur Heart JHome page
R. Linder, J. Oldgren, N. Egberg, L. Grip, G. Larson, A. Siegbahn, and L. Wallentin
The effect of a low molecular mass thrombin inhibitor, inogatran, and heparin on thrombin generation and fibrin turnover in patients with unstable coronary artery disease
Eur. Heart J., April 1, 1999; 20(7): 506 - 518.
[Abstract] [PDF]


Home page
CirculationHome page
J. I. Weitz, E. Young, M. Johnston, A. R. Stafford, J. C. Fredenburgh, and J. Hirsh
Vasoflux, a New Anticoagulant With a Novel Mechanism of Action
Circulation, February 9, 1999; 99(5): 682 - 689.
[Abstract] [Full Text] [PDF]


Home page
CLIN APPL THROMB HEMOSTHome page
J. Fareed
Antithrombin Agents as Anticoagulants and Antithrombotics: Implications in Drug Development
Clinical and Applied Thrombosis/Hemostasis, October 1, 1998; 4(4): 227 - 237.
[Abstract] [PDF]


Home page
CLIN APPL THROMB HEMOSTHome page
R. Altman
Controversies in Antithrombotic Therapy in Cardiovascular Diseases
Clinical and Applied Thrombosis/Hemostasis, January 1, 1998; 4(1): 11 - 24.
[Abstract] [PDF]


Home page
CLIN APPL THROMB HEMOSTHome page
W. F. Baker JR
Thrombosis and Hemostasis in Cardiology: Review of Pathophysiology and Clinical Practice (Part I)
Clinical and Applied Thrombosis/Hemostasis, January 1, 1998; 4(1): 51 - 75.
[Abstract] [PDF]


Home page
StrokeHome page
S. A. Mousa, D.-X. Mu, and B. R. Lucchesi
Prevention of Carotid Artery Thrombosis by Oral Platelet GPIIb/IIIa Antagonist in Dogs
Stroke, April 1, 1997; 28(4): 830 - 836.
[Abstract] [Full Text]


Home page
CLIN APPL THROMB HEMOSTHome page
R. P. Schwarz JR, J.-C. P. Becker, R. L. Brooks, M. J. Hursting, J. L. Joffrion, G. D. Knappenberger, T. P. Kogan, P. W. Kogan, and A. A. McKinney
State-of-the-Art Review: The Preclinical and Clinical Pharmacology of Novastan (Argatroban): A Small-Molecule, Direct Thrombin Inhibitor
Clinical and Applied Thrombosis/Hemostasis, January 1, 1997; 3(1): 1 - 15.
[Abstract] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
C. R. McKenzie, D. R. Abendschein, and P. R. Eisenberg
Sustained Inhibition of Whole-Blood Clot Procoagulant Activity by Inhibition of Thrombus-Associated Factor Xa
Arterioscler. Thromb. Vasc. Biol., October 1, 1996; 16(10): 1285 - 1291.
[Abstract] [Full Text]


Home page
CirculationHome page
R. E. Peverill, R. W. Harper, J. Gelman, T. E. Gan, G. Harris, and J. J. Smolich
Determinants of Increased Regional Left Atrial Coagulation Activity in Patients With Mitral Stenosis
Circulation, August 1, 1996; 94(3): 331 - 339.
[Abstract] [Full Text]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
U. Orvim, R. M. Barstad, G. P. Vlasuk, and K. S. Sakariassen
Effect of Selective Factor Xa Inhibition on Arterial Thrombus Formation Triggered by Tissue Factor/Factor VIIa or Collagen in an Ex Vivo Model of Shear-Dependent Human Thrombogenesis
Arterioscler. Thromb. Vasc. Biol., December 1, 1995; 15(12): 2188 - 2194.
[Abstract] [Full Text]


Home page
Circ. Res.Home page
S. M. Schwartz, D. deBlois, and E. R. M. O'Brien
The Intima : Soil for Atherosclerosis and Restenosis
Circ. Res., September 1, 1995; 77(3): 445 - 465.
[Full Text]


Home page
CirculationHome page
C. B. Granger, J. M. Miller, E. G. Bovill, A. Gruber, R. P. Tracy, M. W. Krucoff, C. Green, E. Berrios, R. A. Harrington, E. M. Ohman, et al.
Rebound Increase in Thrombin Generation and Activity After Cessation of Intravenous Heparin in Patients With Acute Coronary Syndromes
Circulation, April 1, 1995; 91(7): 1929 - 1935.
[Abstract] [Full Text]




HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
Copyright © 1993 by the American College of Cardiology Foundation.